

#### POCT QC Based on Risk Management: How to Develop an IQCP

Ellis Jacobs, Ph.D., DABCC, FACB Director, Scientific Affairs

September 16, 2014



#### **Point-of-Care Testing Characteristics**


A broad based process

Unrestricted to location, personnel or test menu.

A collective, multi-disciplinary effort.

Simple to use technology

Potentially low volume testing





POCT introduces an additional technology


- Different precision
- Biases
- Unique Interferences

POCT results do not necessarily agree with core laboratory results

Quality concerns if manufacturers instructions and controls are not performed as required

Additional testing is ordered when POCT results do not match core lab results or questions about the quality of results present







There is no "perfect" device, otherwise we would all be using it.

Any device can and will fail under the right conditions.

Any discussion of risk must start with what can go wrong with a test (errors).

Laboratory tests are not foolproof.



#### Organizational structure, resources, policies, processes and procedures needed to implement quality management (ISO, CLSI)




In other words... all activities which contribute to quality of testing, directly or indirectly.



## All planned and systematic actions necessary to provide adequate confidence that goods or services will satisfy the customer's needs.


FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION

# Alere POC Testing Knowledge Flow




FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION


Alere Number of CLIA Certificate of Accreditation Labs



Source: CMS CLIA database June 2014








#### CLIA Exempt States: NY (3,990), Washington (3,974)

Source: CMS CLIA database June 2014




#### Exempt Labs = 1,613

Source: CMS CLIA database June 2014



#### Number of CLIA Laboratory Registration Self-Selected Laboratory Types



#### Source: CMS CLIA database June 2014



## **Evolution of QC Practices**

FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION



# So what is QC?

# Where did it come from?

How does QC assure quality data?


FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION




# Operational techniques and activities used to fulfill requirements for quality (ISO)

Internal quality control (IQC) – set of procedures for continuously assessing laboratory work and the emergent results; immediate effect, should actually control release of results (WHO, 1981)











For each test system, the laboratory must test, at a minimum, two levels of external QC materials each day it performs a nonwaived test.

> However, the regulations now allow the laboratory to reduce the frequency of testing external QC materials (equivalent QC procedure) for certain test systems.




**CMS: Equivalent Quality Control Procedures Brochure #4** 






	Evaluation Process		External QC checks
Option 1 System monitors all analytic components	Daily testing with internal monitoring systems	10 consecutive days of passing external QC	At least once per month
Option 2 System monitors some analytic components	Daily testing with internal monitoring systems	30 consecutive days of passing external QC	At least once per week
Option 3 System monitors no analytic components	NA	60 consecutive days of passing external QC	At least once per week





± 1 SD captures 68% of data
 ±2 SD captures 95% of data
 ±3 SD captures 99.7% of data









#### **EP23**


User Defined QC Protocols for *In Vitro* Diagnostic Devices Based on Manufacturer's Risk Mitigation Information and the User's Environment

#### **EP18**

Risk Management Techniques to Identify and Control Laboratory Error Sources

CLSI. *Laboratory Quality Control Based on Risk Management; Approved Guideline.* CLSI document EP23-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.





The designed provides particular band on the resequent for doministic to the design of the test. A public for of photo application developed through the Chanad and Caborators tradende bestime comments provides.

CLINICAL AND LARDORATOWY STANDARDS RESITTUTE

#### Quality control plan development based on risk management (RM)

Systematic approach to analyze, evaluate, control, and monitor risks

CMS' <u>new</u> CLIA IQCP option incorporates RM concepts

ISO14971:2007. Application of risk management to medical devices. www.ISO.org ; Clinical and Laboratory Standards Institute. www.CLSI.org; http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/ Downloads/Survey-and-Cert-Letter-13-54.pdf



Includes key concepts from CLSI EP-23, "Laboratory Quality Control Based on Risk Management"

**IQCP** is not EP-23

Labs are not required to incorporate EP-23

FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION





# Individualized Quality Control Plan (IQCP)

- Customizes QC Plan for each test in its unique environment
- Optimizes use of electronic/integrated controls
- Offers laboratories flexibility in achieving QC compliance
- Adaptable for future advancements in technology
- Incorporates other sources of Quality Information
- Strengthens Manufacturer/Laboratory partnerships
- Formalizes risk management data already maintained within the laboratory
- Provides equivalent quality testing to meet the CLIA QC regulations





Address concerns with "built-in, quality assessment" technology in evaluating test quality

- IQCP validates, at a minimum, that manufacturer recommendations adequately ensure analytical quality

Ensure test result quality by eliminating significant risk in the entire testing process

Allow sites flexibility to develop quality strategies appropriate for their specific testing situation



Is it voluntary?	• Yes	
Who is eligible?	<ul> <li>All specialties <u>except</u> pathology and cytology</li> </ul>	
What is involved?	<ul> <li>Risk assessment</li> <li>Quality control plan</li> <li>Quality assessment for ongoing effectiveness</li> </ul>	



Key concepts from EP-23 will be an acceptable alternative QC policy. The New CLIA QC policy will be entitled Individualized Quality Control Plan (IQCP)

IQCPs are a formal representation and compilation of many things laboratories currently do for quality.

IQCPs permits the laboratory to customize its QC plan according to environment, reagents, testing personnel, specimens, and test system.

IQCP will be voluntary: Laboratories will have two choices for QC compliance: 1) Two levels of QC per day or, 2) IQCP. Package insert requirements must be met.

#### Education period: 1/1/14-1/1/16


FOR INTERNAL US

EQC will be phased out at the end of the education and transition period





- <u>CMS/CLIA Website:</u> http://www.cms.hhs.gov/clia/
- CMS CLIA Central Office: 410.786.3531
- IQCP Link: IQCP@cms.hhs.gov
- EP23 Workbook





"On-Board" or Analyzer QC – built-in device controls or system checks
Internal QC – laboratory-analyzed surrogate sample controls
External QC – blind proficiency survey
Other types of QC – control processes either engineered by a manufacturer or enacted by a laboratory to ensure result reliability

## Alere Accrediting Agencies Updates

Accredited laboratories should continue to meet their accrediting organizations' QC standards until they receive notice from their AOs. COLA be presented criteria in June 18, 2014 webinar

TJC introduced new IQCP Standard on March 24, 2014

Laboratories may use CLIA QC regulations, EQC, or IQCP CAP requirements will be published with the July 2015 checklist updates

CMS will solicit accrediting organizations (AOs) to determine their interest in IQCP.



### Sources of Errors in POCT





# Alere Key Processes in Laboratory Workflow Path

Preexamination	Examination	Postexamination
(Preanalytical)	(Analytical)	(Postanalytical)
Processes	Processes	Processes
<ul> <li>Examination ordering</li> <li>Sample collection and labeling</li> <li>Sample transport</li> <li>Sample transport and accessioning</li> <li>Preexamination sample processing</li> </ul>	<ul> <li>Examination</li> <li>Results review and follow-up</li> <li>Medical review</li> </ul>	<ul> <li>Results reporting</li> <li>Results archiving</li> <li>Sample archiving</li> <li>Charging for examinations, where applicable</li> </ul>

CLSI. Laboratory Documents: Development and Control; Approved Guideline—Fifth Edition. GP02-A5. Wayne, PA: Clinical ALUSE of and Laboratory Standards Institute; 2006.



	1997	2007
Preanalytical	68%	62%
Analytical	13%	15%
Post-analytical	19%	23%

Plebani M, Carraro P, Clin Chem 1997;43:1348-1351 Carraro P, Plebani M, Clin Chem 2007;53;1338-1342



#### Potential Impact of POCT on Laboratory **Errors**

#### **Pre-Analytical**



Patient Identification **Specimen Identification** Improper result validation (QC) **Post-Analytical** 


Routing

Excessive turn-around time

#### Analytical

**Method Calibration** Interferences Results out of measurement range Quality Assessment (EQA/PT)





#### N = 225 O'Kane M, et al, Clin Chem 2011;57:1267-1271

FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION



Test Type	# of Tests	# of defects	% of defects
Blood gas/electrolytes	22,687	119	0.52
Blood gas/electrolytes/ troponin I	5,809	10	0.17
Pregnancy	8,879	14	0.158
Glucose	30,389	71	0.02
Drugs of Abuse	247	1	0.4
Hb A1c	1,236	8	0.65
Urinalysis	64,370	2	0.003
Blood Ketones	1,087	0	0

O'Kane M, et al, Clin Chem 2011;57:1267-1271



Score	Acutal n (%)	Potential n (%)
1	116 (51.2)	6 (2.7)
2	109 (48.4)	175 (77.8)
3	0 (0)	3 (1.3)
4	0 (0)	33 (14.7)
5	0 (0)	8(3.6)

O'Kane M, et al, Clin Chem 2011;57:1267-1271



# Designed out of the product


Tested for

Warned about

monitored

FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION





Ehrmeyer S, Lassig R. Clin Chem Lab Med 2007;45(6):766-773

# Alere Patient/Sample Identifcation



Pre-barcoded arterial syringe for positive patient identification



Establishes and maintains sample ID throughout testing process



## **Preanalytical Error Reduction**



#### Reduced Analytical Risks

- Glucose-specific strip technology
- Individually foil wrapped and barcoded strips –
  - reduces risk of contamination
- assure fresh reagents for each test
- only approved lots can be used

Reduced Risk of Sampling Errors


• Test begins when adequate sample is detected, reducing risk of short-sampling and over-sampling errors



Use of electronic checks, including any instrument software features that serve as error detection or prevention mechanisms


Use and number of surrogate samples, where appropriate, to be included as part of the QC procedure

Testing of controls that are engineered into the test system






## Integrated Surrogate Control Alere Quantitative Immunochromatography



Alere Surrogate QC doesn't detect all errors






Includes all forms of quality control other than the measurement of a surrogate sample, usually integrated into the device

- electronic QC (which simulates signals electronically)
- automated procedural controls (which ensure that certain steps of the procedure occur appropriately), ex. Immunochromatography test kits
- automated internal quality controls (which may, for example, ensure the quality of a raw signal)
- diagnostic pattern recognition systems

# Procedural Control Immunochromatography – Urine Dip






IMS are a collection of hardware and software that detect errors and prevent the effect of the error from occurring

• Example: Noise in the signal of a patient sample is detected, the result is flagged and not reported

IMS are not new – although improved, they have been in systems for over 30 years







Room temp storage 11 measured results 10 calculated results ~30 second test time



		csysadmin		EPOC Lin	k @ 192.168.10.10	: 45002 🖋 DB : 🖋	2.1.0 Log	Of
POC Manager > T	ests > Blood Tests							
Blood Tests QA	Tests EPOC System							
and the second second	st 7 days) - 24 tests		- Herrison		La (22 (22 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	To : 10/29/2008 🗸	Refresh	
My Tests	Select Filter Type 💌	Select Filter V	Select Filter Value From : 10/23/2008 V To : 10/					
Date/Time	Patient ID	Operator	Host	Reader	Status	Critical	LIS	
Date/ Hine								
29-Oct-08 14:33		administrator	EPOC Host 0055B8C	Aldin QA Rdr	Incomplete		Not Sent	
	administrat 12	administrator administrator	EPOC Host 0055B8C EPOC Host 0055B8C	Aldin QA Rdr Aldin QA Rdr			Not Sent Not Accepted	-
29-Oct-08 14:33	administrat 12				Incomplete	-		
29-Oct-08 14:33 29-Oct-08 14:27	administrat 12 administrat 11	administrator	EPOC Host 0055B8C	Aldin QA Rdr	Incomplete iQC	4 2	Not Accepted	
29-Oct-08 14:33 29-Oct-08 14:27 29-Oct-08 14:23		administrator administrator	EPOC Host 0055B8C EPOC Host 0055B8C	Aldin QA Rdr Aldin QA Rdr	Incomplete iQC Incomplete	94 94 12	Not Accepted Not Sent	
29-Oct-08 14:33 29-Oct-08 14:27 29-Oct-08 14:23 29-Oct-08 14:14	administrat11	administrator administrator administrator	EPOC Host 0055B8C EPOC Host 0055B8C EPOC Host 0055B8C	Aldin QA Rdr Aldin QA Rdr Aldin QA Rdr	Incomplete iQC Incomplete Incomplete		Not Accepted Not Sent Not Sent	



Every time the Host and Reader connect, the Reader undergoes an automatic, 2 level, electronic QC test.

This will repeat every 8 hours if needed.

### The Reader monitors the testing environment:

- The operating conditions are 15°-30° C, 400-825 mm Hg atmospheric pressure and <85% humidity.
- The Reader has internal thermometers and barometers and will shut down if these ranges are exceeded.
- The internal QC checks will fail if humidity is >85



An audible beep is produced when adequate sample is applied to the card.

# The system will flag the following conditions and not deliver a test result when:

- Using an expired card
- Rerunning an already used test card
- Putting in too little sample
- Introducing the sample too rapidly, too slowly or sample with an air bubble.
- Introducing the sample at the wrong time




Internal monitoring systems don't detect all errors, because:

- Complexity of instrument systems prevents perfect failure mode models
- There is management pressure to release new products quickly
- There is insufficient knowledge to "design things right the first time"




#### are not completely redundant

#### do not detect all errors



FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION






### As autonomation reduces errors in the box, further reductions must occur outside the box




# **Developing the Quality Control Plan**

FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION





# Process to Develop and Maintain (CQI) a Quality Control Plan (QCP)



CLSI. Laboratory Quality Control Based on Risk Management; Approved Guideline. EP23-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

# Alere, Where is the Risk Here?






The chance of suffering or encountering harm or loss (*Webster's Dictionary and Thesaurus*. Ashland, OH: Landall, Inc.; 1993).

Risk can be estimated through a combination of the probability of occurrence of harm and the severity of that harm (ISO/IEC Guide 51).

The potential for an error to occur that could lead to patient/staff harm



Systematic application of management policies, procedures, and practices to the tasks of analyzing, evaluating, controlling, and monitoring risk (ISO 14971)





# Manufacturer's package insert including but not limited to:

- Intended use
- Limitations
- Environmental requirements
- QC frequency
- Specimen requirements
- Reagent storage
- Maintenance
- Calibration
- Interfering substances



Manufacturer's operator manual

Troubleshooting guide

Manufacturers' alerts and bulletins

Verification or establishment of performance specifications

**Training manuals** 



Testing personnel qualifications, training, and competency records

QC/Proficiency testing data

QA information including corrective actions taken


Scientific publications/journals


Internet/database searches

Laboratory community/specialty forums



- Brainstorming
- 5 Whys
- Fishbone diagrams
- Process mapping






G. Cooper, BioRad. 2007 AACC QC Webinar

# Alere EP23 Workbook Key Process Steps


- 1. Operator training and competency
- 2. Reagent/calibrator/parts procurement and storage
- 3. Patient sample acceptability evaluation
- 4. System startup
- 5. System calibration
- 6. Loading and testing of patient samples
- 7. Proper device function
- 8. Test result review

Alere Process Map – High Level



CLSI. Laboratory Quality Control Based on Risk Management; Approved FOR INTERNAL Guideline. EP23-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

# **Nere** Fishbone Diagram of Potential Failure Modes



CLSI. Laboratory Quality Control Based on Risk Management; Approved Guideline. EP23-A. Wayne, PA: Clinical and

FOR INTERNAL USE ONLY Laboratory Standards Institute; 2011.



	Severity of Harm						
Probability of Harm	Negligible	Minor	Serious	Critical	Catastrophic		
Frequent	unacceptable	unacceptable	unacceptable	unacceptable	unacceptable		
Probable	acceptable	unacceptable	unacceptable	unacceptable	unacceptable		
Occasional	acceptable	acceptable	acceptable	unacceptable	unacceptable		
Remote	acceptable	acceptable	acceptable	acceptable	unacceptable		
Improbable	acceptable	acceptable	acceptable	acceptable	acceptable		

CLSI. Laboratory Quality Control Based on Risk Management; Approved Guideline. EP23-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION



Frequency Score	Description
1	Likely to occur very infrequently, on the order of once in a hundred years.
3	Likely to occur infrequently, on the order of once every five years.
5	Likely to occur with moderate frequency, on the order of once a year.
7	Likely to occur with significant frequency, on the order of once a month.
10	Likely to occur with high frequency, on the order of one or more times a day.



Severity Score	Description
1	Negligible = inconvenience or temporary discomfort
3	Minor = temporary injury or impairment not requiring professional medical intervention
5	Serious = injury or impairment requiring professional medical intervention
7	Critical = permanent impairment or life-threatening injury
10	Catastrophic = patient death

ISO 14971 Medical Devices – Application of risk management to medical devices, 2007 <sup>72</sup>

## Alere Detectability Scoring

Detectability Score	Description
1	Very easy to detect, high visibility & multiple steps in process that follows step where failure might occur, failure is virtually certain to be detected.
3	Fairly easy to detect, with moderately high visibility & several steps in process that follows step where failure might occur, significant likelihood that failure will be detected.
5	Moderately detectable, with fair degree of visibility and at least two or more steps in process that follow step at which failure might occur.
7	Moderately difficult to detect, with low visibility and only one step in process that follows step where failure might occur, low likelihood that failure will be detected.
10	Extremely difficult to detect, with process being virtually invisible to others and with not steps in process that follow step where the failure might occur, extremely no chance that failure will be detected.



CI = Frequency x Severity x Detectability

CI Score	Relative Importance
>/ 250	Significant
100 – 249	Less Important
<100	Not Important

#### Coler-Goldwater Specialty Hospital and Nursing Facility FAILURE MODE, EFFECT, and CRITICALITY ANALYSIS WORKSHEET

#### **Topic-Infection Prevention and Control**


#### Explore causes of failure and develop risk reduction strategies for steps that score 250 or higher and/or for those steps deemed necessary to address regardless of their FMECA score

(1) Step in the Process	(2) Possible Failure Mode	(3) Effect(s) of Failure	(4) Freq	(5) Severity	(6) Detection	(7) CI	(8) Causes of Failure	(9) Risk Reduction Strategies
	What could go wrong?	What are the consequences of the failure?	How likely is it that this failure will occur?	If this failure occurred, how likely is it that harm will occur?	How likely is it that this failure will be detected?		Why might this failure happen?	Actions to reduce the failure from happening
#1								
#2								
#3								
#4								
#5								
#6								
#7								
#8								
Etc.								

**.t**.



- Implement the PLAN
- Monitor, verify and improve the PLAN, when needed
- QA step is nothing new the process is required for all testing processes
  - Include in lab's overall QA plan



Plan-Do-Check-Act for Continuous Quality Improvement (CQI)



QC must be able to detect mistakes to enable immediate correction

Risks and costs must be weighed

QC is only one part of the quality control plan / quality management system

Not all laboratories have the same competencies and organization

Science and common sense must converge

FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION



Summarizes the potential errors for a device and how the lab will address them.

Can be high level or very detailed - depends on the device, the laboratory, and the clinical application and can vary from lab to lab.

Is scientifically based. It depends on the extent to which the device's features or actions achieve their intended purpose and the laboratory's expectations for ensuring quality test results.



Risk management is something laboratories are already doing..

An IQCP assesses the medical need for test, performance requirements, and weaknesses in the testing process as well as actions to address those risks.

Each IQCP is unique because the combination of device, setting, medical requirements and operators may differ between laboratories.


An IQCP is the industry standard. It depends upon the extent to which the device's features achieve their intended purpose in union with the laboratory's expectation for ensuring quality results.

Once implemented, the IQCP is monitored for effectiveness and modified as needed to maintain risk at a clinically acceptable level.



- <u>CMS/CLIA Website:</u> http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html?redirect=/clia/
- CMS CLIA Central Office: 410-786-3531
- IQCP Link: http://www.cms.gov/Regulations-and-Guidance/ Legislation/CLIA/Individualized\_Quality\_Control\_Plan\_IQCP.htm
- <u>CMS IQCP Questions</u>: Any questions about IQCP should be forwarded to IQCP@cms.hhs.gov
- Cause and Effect Diagrams: Description and example http://www.ihi.org/resources/Pages/Tools/CauseandEffectDiagram.aspx
- **CLSI Link:** http://www.clsi.org





# QUESTIONS

### ellis.jacobs@alere.com